{"corpus_id":209180317,"paper_sha":"280cb04fd570fc483d129f521747ad4f655a865d","doi":"10.1016/S0140-6736(19)32518-8","arxiv_id":null,"pmid":31836196,"pmcid":"6934233","mag_id":2995392303,"dblp_id":null,"acl_id":null,"title":"Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial","year":2019,"publication_date":"2019-12-01","venue":"The Lancet","journal":{"name":"Lancet (London, England)","pages":"2263 - 2270","volume":"394"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Multicenter Study","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":30,"citation_count":96,"influential_citation_count":1,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adolescent","mj":false,"ui":"D000293"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Angiotensin II Type 1 Receptor Blockers","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D047228"},{"d":"Aorta","mj":false,"qs":[{"q":"diagnostic imaging","mj":true,"ui":"Q000000981"},{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D001011"},{"d":"Child","mj":false,"ui":"D002648"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Drug Administration Schedule","mj":false,"ui":"D004334"},{"d":"Echocardiography","mj":false,"ui":"D004452"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Irbesartan","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D000077405"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Marfan Syndrome","mj":false,"qs":[{"q":"diagnostic imaging","mj":false,"ui":"Q000000981"},{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D008382"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"United Kingdom","mj":false,"ui":"D006113"},{"d":"Young Adult","mj":false,"ui":"D055815"}],"chemicals":[{"n":"Angiotensin II Type 1 Receptor Blockers","ui":"D047228","reg":"0"},{"n":"Irbesartan","ui":"D000077405","reg":"J0E2756Z7N"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://www.thelancet.com/article/S0140673619325188/pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/280cb04fd570fc483d129f521747ad4f655a865d","s2_open_access_license":"CCBY","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Summary Background Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. Methods We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6–40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794. Findings Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12–28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of −0·22 mm per year (−0·41 to −0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means −0·10 per year, 95% CI −0·19 to −0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events. Interpretation Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications. Funding British Heart Foundation, the UK Marfan Trust, the UK Marfan Association.","claims":[{"public_id":"cl_de573c10f13a1344bba925fe85fddddc","status":"active","text":"Irbesartan also reduced the rate of change in aortic Z score relative to placebo.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_de573c10f13a1344bba925fe85fddddc"},{"public_id":"cl_c207b456edfa22c82071aeaedd835c4e","status":"active","text":"Irbesartan reduced the rate of aortic root dilatation compared with placebo in children and young adults with Marfan syndrome.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c207b456edfa22c82071aeaedd835c4e"},{"public_id":"cl_50c93e15004534aa3b73bc7379549a28","status":"active","text":"Irbesartan was well tolerated, with no observed difference in serious adverse event rates versus placebo.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_50c93e15004534aa3b73bc7379549a28"}],"concepts":[{"public_id":"co_221df01b0edf5f82efe89fe93eb9d502","status":"active","name":"core laboratory","description":"A centralized blinded reading unit that analyzed the trial imaging data.","types":["analysis unit"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_221df01b0edf5f82efe89fe93eb9d502"},{"public_id":"co_630218293ed24141a78dcd2ca30a74e5","status":"active","name":"aortic root dilatation","description":"Progressive enlargement of the aortic root measured over time by echocardiography.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_630218293ed24141a78dcd2ca30a74e5"},{"public_id":"co_6432c80e012f59dafeef88c1192306a1","status":"active","name":"Marfan syndrome","description":"A heritable connective tissue disorder associated with aortic enlargement and related complications.","types":["condition"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6432c80e012f59dafeef88c1192306a1"},{"public_id":"co_817f0ffbd584c92cfbd1f1c896727eed","status":"active","name":"serious adverse events","description":"Clinically significant harmful events monitored as a safety outcome.","types":["safety outcome"],"aliases":["SAEs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_817f0ffbd584c92cfbd1f1c896727eed"},{"public_id":"co_89e7c3612db441a4e595085d053f46dc","status":"active","name":"aortic complications","description":"Adverse clinical events related to the aorta, including dissection and rupture.","types":["clinical outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_89e7c3612db441a4e595085d053f46dc"},{"public_id":"co_9b187ad6634cef838a05939407fcd6a6","status":"active","name":"placebo","description":"An inactive comparison treatment used in the randomized trial.","types":["control"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9b187ad6634cef838a05939407fcd6a6"},{"public_id":"co_aa02c9a30d7d19ceb03289e1febcc5be","status":"active","name":"irbesartan","description":"A long-acting selective angiotensin II receptor blocker used here as the investigational treatment.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_aa02c9a30d7d19ceb03289e1febcc5be"},{"public_id":"co_b0953d149bb119d807a1e89acdd115e2","status":"active","name":"echocardiography","description":"An ultrasound imaging method used to measure aortic diameter.","types":["measurement technique"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b0953d149bb119d807a1e89acdd115e2"},{"public_id":"co_c68794fa00ccae49505ee5b90a615f86","status":"active","name":"double-blind randomised trial","description":"A randomized controlled trial in which treatment allocation is concealed from participants and investigators.","types":["study design"],"aliases":["double-blind randomized trial"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c68794fa00ccae49505ee5b90a615f86"},{"public_id":"co_ffed44582d43dfc7b7b1322b4cc9951d","status":"active","name":"aortic Z score","description":"A standardized measure of aortic root size adjusted for body size or age.","types":["measurement"],"aliases":["Z score"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ffed44582d43dfc7b7b1322b4cc9951d"}],"external_ids":{"DOI":"10.1016/S0140-6736(19)32518-8","ArXiv":null,"PubMed":31836196,"PubMedCentral":"6934233","MAG":2995392303,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://www.thelancet.com/article/S0140673619325188/pdf","landing_url":"https://www.semanticscholar.org/paper/280cb04fd570fc483d129f521747ad4f655a865d","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631828,"paper_uid":"50efcf73-74a7-4438-8aee-d84947fc8666","canonical_identity":{"paper_id":631828,"paper_uid":"50efcf73-74a7-4438-8aee-d84947fc8666","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/209180317"}